Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
Table 1
Baseline characteristics of the study participants.
Characteristics
LAI antipsychotic monotherapy group ()
Combination of LAI and oral antipsychotics group ()
Median (IQR)
Age, years
34.0 (27.0, 47.0)
34.0 (27.0, 41.0)
Body weight, kg
59.2 (50.5, 69.5)
61.2 (56.3, 70.8)
Body mass index, kg/m2
23.9 (21.2, 25.0)
24.0 (22.4, 24.3)
Age at onset of illness, years
32.0 (22.8, 41.5)
30.0 (22.2, 35.0)
Duration of illness, years
3.0 (1.0, 4.5)
2.0 (0.5, 7.5)
Dose of LAI antipsychotic, mg (flupenthixol decanoate equivalent)
33.0 (20.0, 63.5)
40.0 (20.0, 50.0)
Dose of oral antipsychotic, mg (chlorpromazine equivalent)
0.0 (0.0, 0.0)
333.0 (200.0, 600.0)
(%)
Sex (% male)
10 (40.0)
34 (55.7)
Marital status, % single
16 (64.0)
47 (77.0)
Psychiatric comorbidities, (%)
Bipolar disorder
0
5 (8.2)
Major depressive disorder
1 (4.0)
2 (3.3)
Catatonia
0
1 (1.6)
Comedications, (%)
Anti-EPS
20 (80.0)
53 (86.9)
Sedatives/anxiolytics
13 (52.0)
30 (49.2)
Mood stabilizers
2 (8.0)
5 (8.2)
Antidepressants
1 (4.0)
6 (9.8)
Substances, (%)
Alcohol
6 (24.0)
16 (26.2)
Amphetamine
4 (16.0)
5 (8.2)
Cannabis
0
3 (4.9)
Tobacco
5 (20.0)
26 (42.6)
Others
1 (4.0)
1 (1.6)
LAI antipsychotics
Fluphenazine decanoate
2 (8.0)
11 (18.0)
Flupentixol decanoate
14 (56.0)
30 (49.2)
Haloperidol decanoate
6 (24.0)
12 (19.7)
Paliperidone palmitate
3 (12.0)
4 (6.6)
Risperidone
0 (0.0)
4 (6.6)
EPS: extrapyramidal side effect; LAI: long-acting injectable. .